Roche won't pursue Herceptin patents in India..... Stada quickly pulls off deal for OTC maker Thorton & Ross..... NICE denies Pfizer lung cancer drug in final guidance..... Pharma M&A; gets soft in second quarter..... Boehringer Ingelheim to close U.S. plant, whack 240 workers..... Novartis' Bexsero vaccine receives Australian approval for MenB disease..... Galectin Q2 2013 net loss narrows..... Pharma Security Group introduces new medication reminder service..... Symmetry acquires rights to biosynthetic testosterone production technology..... ScripsAmerica, WholesaleRx sign joint venture agreement..... Litera acquires AxxiTRIALS clinical trials portal solution..... InnoPharma introduces generic version of Campral..... CFDA renews GMP status for TPI?s Longquan County facility..... GW Pharma submits IND application with US FDA for Sativex phase III clinical trial..... Easing U.S. drug spending gives Sanofi, Novo room to raise insulin prices..... Avanir, Sandoz settle Nuedexta patent litigation..... US FDA approves Silvergate Pharmaceuticals' Epaned to treat hypertension..... Novartis opens internal China probe after former rep demanded $800K..... South Africa's Adcock still in exclusive buyout talks with CFR..... Which are pharma's top 4 innovators? Hint: It's not the big guys..... NY fund trustee to continue push for exec-pay clawbacks at Abbott..... Teva CEO wants to hook up with Brazil, China partners..... Forest hits setback on new COPD drug, one of its key hopes for sales growth..... Tekmira commences Phase I/II study of TKM-PLK1..... European Commission grants additional indication for GSK?s Tyverb..... MHRA approves Ultragenyx CTA of Phase I/II trial of UX003..... Russia's Pharmstandard OJSC agrees to acquire Bever Pharma..... Sunovion Pharma and Afraxis establish novel drug discovery alliance..... WestPharmaceutical launches Daikyo D4 Elastomer stopper..... Aegis wins New Zealand patent for fast acting formulations of triptans..... Vifor Pharma and Zeria Pharma sign licensing agreement for Ferinject in Japan..... ProMetic selects Alpha1-Antitrypsin as second plasma-derived therapeutic..... USPTO issues notice of allowance for Sangamo genome modification technology..... Agilent, SomaLogic sign deal to expand access to proteomic assay..... Amarantus reports positive data from MANF retinitis pigmentosa study..... Eureka Genomics launches next-generation sequencing & bioinformatics services using Ion Proton System..... INVISTA, SilicoLife to develop new technologies for bio-derived processes..... Lipotriad introduces new and improved AREDS 2 Eye Vitamin Formula..... Merrimack Pharmaceuticals' bispecific antibody wins two FDA designations..... Prismic secures new worldwide agreement covering several therapeutic products..... China sales rep says Novartis ordered her to bribe doctors..... Tivicay marks beginning of end in growth of HIV branded market, forecast says..... Boehringer sales tick upward 3% on big Pradaxa leap..... As Sativex takes on Europe bit by bit, GW Pharma works on FDA..... MannKind touts good news from Afrezza inhaled insulin trial..... Eli Lilly and Company's Phase III study of necitumumab meets primary endpoint..... Derma Sciences begins shipment of honey-based over-the-counter product..... BD presents new prefillable polymer syringe..... Sanford-Burnham, Pfizer partner to find new treatment for diabetes..... Stemcell Technologies taps BioLife's CryoStor cGMP freeze media for primary cell products..... New Novartis chair Reinhardt embarks on strategic review. Are divestments next?..... Torrey Pines and BioMotiv join hands for drug development..... New FDA guidance cites CSM techniques from CluePoints for improved data quality..... How can pharma reps score face time with doctors?..... Lawmakers demand Purdue Pharma's list of suspect OxyContin prescribers..... Mylan assures India it won't dismiss domestic market with Agila buy..... Pharmstandard's $590M Bever buy beefs up OTC unit for spinoff..... Regeneron expanding amid growing Eylea demand..... ViiV's newly minted HIV fighter Tivicay to cost $14K per year..... ViiV Healthcare's Tivicay wins FDA approval to treat HIV-1..... Amgen, Servier announce completion of product collaboration transaction..... TherapeuticsMD commences Phase I study of vulvar and vaginal atrophy candidate..... Biocon launches Alzumab in India for psoriasis patients..... Advanomics wins research grant for cancer drug candidate..... Avanir signs co-promotion agreement with Merck for diabetes drugs..... ANI Pharmaceuticals signs deal to develop oral soft gel prescription product..... Lundbeck announces availability of oral anti-epileptic drug ONFI..... Teva, Perrigo launch generic equivalent to Temodar in US..... XstalBio introduces new patented reconstitution technology for biologic drugs delivery..... Breckenridge to acquire certain assets of Cypress Pharmaceuticals..... US FDA approves Alere Determine HIV 1/2 Ag/Ab Combo..... MWV unveils Shellpak Renew with Optilock technology..... Quest Diagnostics launches Opioid therapy genetic test based on CYP450..... Sanofi 'confident' about China ops as officials launch bribery probe..... LAT: Purdue keeps 'risky' OxyContin prescribers' names private..... India's Aurobindo to build up sterile injectables operations..... Roche chief's comments about deal discipline push shares up..... Russia's Pharmstandard still weighing OTC unit sale, exec says..... FDA: Infections prompt recall of all Specialty Compounding's sterile meds..... Celgene's Pomalidomide oral anti-cancer therapy wins European Commission approval..... Berg, US DOD sign prostate cancer research deal..... USPTO issues patent to Cerecor's FP01 antitussive..... Curemark wins patent for CM-1212 to treat drug, alcohol addiction..... Aurobindo Pharma agrees to buy stake in Celon Lab?s plant and Silicon Life Sciences..... Akrikhin to produce five additional MSD drugs..... Dendreon's Provenge sales off again, expected to miss for the year..... Onyx CEO dismisses rumors that Amgen alone is still in the hunt..... European Commission grants J&J;, Celgene blood cancer approvals..... Allergan takes latest IP hit as India revokes 2 patents..... Sun has terrific quarter, except for that Pfizer thing..... GSK launches $50m venture capital fund to invest in bioelectronics..... ScinoPharm Changshu and Sundia MediTech collaborate on CRAMS in China..... Athersys receives funding for clinical advancement of stem regenerative medicine program..... Onyx and Idis partner to initiate Managed Access Program in Europe..... Aurobindo Pharma plans injectables Unit-IV manufacturing plant expansion..... Regeneron?s East Greenbush manufacturing plant enters second phase construction..... Ranbaxy obtains site for building $35m Greenfield facility in Malaysia..... RSS NEWSFEED....

Welcome to
The Academy of
Pharmaceutical Sciences

The Academy of Pharmaceutical Sciences is the professional body for the Pharmaceutical Sciences in United Kingdom. A Pharmaceutical Scientist is an individual who contributes to bringing a new drug from concept through to a medicinal product. This includes, but is not exclusive to, individuals in academia, industry, regulation, clinical research and manufacturing.

The mission of the Academy of Pharmaceutical Sciences is to champion innovation and opportunity in Pharmaceutical Sciences for the delivery of medicines.

In order to achieve this mission, our aims are to:

Promote the Pharmaceutical Sciences to stakeholders to facilitate understanding and achieve engagement
Share learning, drive collaboration, partnership and innovation
Deliver insights into industry and academic roles for aspiring scientists

Latest News

3rd Annual MIBio Conference - 29th October 2013, Fitzwilliam College, Cambridge University
MONDAY, 8 JULY 2013
Following on from the great success of MIBio 2012 the Formulation Science and Technology Group (FSTG) of the Royal Society Chemistry (RSC) and the Academy of Pharmaceutical Scientists (APS) are pleased to announce: 3rd Annual MIBio Conference Molecular Interactions in Biopharmaceutical Formulations High concentration biologics: Viscosity, characterisation and delivery 29th October 2013, Fitzwilliam College, Cambridge University Also assisting, to further ensure success of the event, are The Joint Colloids Group (RSC) and the Knowledge Transfer Network (KTN). The MIBio conference series engages world leading experts from academia and industry in discussions on how the latest molecular interaction based discoveries can be exploited in biopharmaceutical formulation to produce more effective and safer therapeutic products. The main focus of MIBio 2013 will be on the viscosity, characterisation and delivery of high concentration biologics â€“ the big challenges in biopharmaceutical formulation. This event will take place on 29th October, 2013 in the scenic setting of Fitzwilliam College at Cambridge University (Cambridge, UK). We are building on the extremely positive feedback received from speakers, delegates and sponsors after the 2012 conference to make MIBio 2013 an even more engaging, interactive and memorable event. High calibre speakers will cover a number of topics related to formulating high concentration proteins, including fundamental understanding of interactions in crowded protein solutions and exploiting the knowledge in rational design of concentrated protein therapeutics. The speakers list includes: • Jai Pathak (MedImmune, USA) • Davendra Kalonia (University of Connecticut, USA) • Jose Garcia de la Torre (Universidad de Murcia, Spain) • Cecile Dreiss (Kingâ€™s College London, UK) • German Rivas Caballero (CSIC, Spain) To register please visit our conference website at: www.mibio-conference.com. For more information please contact conference secretariat via: [email protected]

Have you read this article "Towards Global Stability Protocols: A Decade of Lost Opportunities?"
TUESDAY, 25 JUNE 2013
You will find it on the website of the Joint Pharmaceutical Analysis Group (www.jpag.org). Written by Dr Dave Elder, it is reproduced with permission of European Pharmaceutical Review. While you are on the website, look for details of the forthcoming symposium on "Meeting stability challenges" to be held at the Royal Society of Chemistry on Thursday 4th July. This symposium is highly relevant to pharmaceutical analysts, quality control analysts, quality assurance professionals, qualified persons and regulatory affairs professionals from pharmaceutical industry, CMOs and contract laboratories. We are anticipating a big attendance for this topical subject so book now to avoid disappointment. advancing pharmaceutical analytical science jpag.org

APS Biopharmaceutics Applied biopharmaceutics - understanding bioequivalence, biowavers and IVIVCs
TUESDAY, 25 JUNE 2013
10th July 2013, MSD Innovation Centre, Hoddesdon Biopharmaceutical properties help guide formulation design and choice of delivery system, however profiling dosage form performance under conditions which are relevant to in vivo conditions remains a challenge for pharmaceutical scientists. Using this information to predict clinical performance or optimise clinical study design is a further challenge for product development teams. This meeting aims to provide a forum for scientific discussion of the current best practice and emerging science for these themes. Particular emphasis is given to new methods to characterise the in vitro performance of oral formulations and the use of biomodelling to predict clinical performance. Invited speakers include experts from industrial, academic and regulatory groups who will share current perspectives on the use of biopharmaceutics data to support product development. This meeting is aimed at industrial and academic scientists working in the areas of biopharmaceutics, formulation design, regulatory CMC and analytical development. Scientists who are new to the area will also find the symposium useful for gaining a broad understanding of the key scientific and technical issues. There will be an opportunity to submit poster presentations and three posters will be selected for a short talks session. To review the programme and speakers, view the delegate fees and to register for the conference, please visit the APS website here: http://www.apsgb.org/Events/20130710/Default.asp

SME showcase at APS PharmSci 2013
TUESDAY, 25 JUNE 2013
The APS is now actively seeking potential participants for the SME Showcase at APS PharmSci 2013 and would ask all interested organisations to contact either Bill Dawson or Maureen Coleman directly with a short abstract (250 words) to allow selection for the programme. It will be a competitive process with a number of places held for exhibitors at APS PharmSci 2013. The SME Showcase has been run since the APS was formed and has been hugely successful with a range of companies able to display their successful products and services and network with potential clients and partners. During this plenary session, the format for each SME will constitute a 5-10 minute presentation followed by a brief Q and A and then a day of potential networking with members of the audience. With strong pharmaceutical science interests, medicines, diagnostics, devices and services are all valid subjects for the Showcase. Closing date for abstract submission is June 28th 2013 and notification of success will be by July 19th 2013. Please contact: [email protected] for submission of abstracts [email protected] submission of abstracts For more information on APS PharmSci 2013, please visit us online at: http://www.ukpharmsci.org/Default.asp

Upcoming Events

APS PharmSci 2013
2 - 4 September 2013

Vacancies

View all Vacancies
Advertise your job vacancies